Literature DB >> 37870

Improved physical performance as a therapeutic objective in patients with angina.

A S Ling, J T Groel.   

Abstract

1 Improvement in physical performance, based on exercise tolerance, self-assessed work and physician-rated functional capacities, is proposed as a measure of efficacy of anti-anginal therapy in the rehabilitation of the cardiac patient. 2 Improved physical performance parallels changes in frequency of anginal attacks and a nitroglycerin requirements following beta-blocker therapy. 3 Nadolol (a beta-blocker), given once daily is as effective as propranolol, given four times daily as an anti-anginal agent.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 37870      PMCID: PMC1429329          DOI: 10.1111/j.1365-2125.1979.tb04686.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  18 in total

Review 1.  Drug therapy: Propranolol.

Authors:  D G Shand
Journal:  N Engl J Med       Date:  1975-08-07       Impact factor: 91.245

Review 2.  The clinical pharmacology of beta-adrenoceptor-blocking drugs.

Authors:  M E Conolly; F Kersting; C T Dollery
Journal:  Prog Cardiovasc Dis       Date:  1976 Nov-Dec       Impact factor: 8.194

3.  A NEW ADRENERGIC BETARECEPTOR ANTAGONIST.

Authors:  J W BLACK; A F CROWTHER; R G SHANKS; L H SMITH; A C DORNHORST
Journal:  Lancet       Date:  1964-05-16       Impact factor: 79.321

4.  Clinical pharmacology of a beta-adrenergic-blocking agent (Nethalide).

Authors:  A C DORNHORST; B F ROBINSON
Journal:  Lancet       Date:  1962-08-18       Impact factor: 79.321

5.  Hypertension and compliance: implications for the primary physician.

Authors:  R N Podell; L R Gary
Journal:  N Engl J Med       Date:  1976-05-13       Impact factor: 91.245

Review 6.  Myocardial ischemia (first of three parts).

Authors:  L D Hillis; E Braunwald
Journal:  N Engl J Med       Date:  1977-04-28       Impact factor: 91.245

7.  Pharmacology of nadolol (SQ 11725), a beta-adrenergic antagonist lacking direct myocardial depression.

Authors:  R J Lee; D B Evans; S H Baky; R J Laffan
Journal:  Eur J Pharmacol       Date:  1975 Sep-Oct       Impact factor: 4.432

8.  The management of the patient with angina.

Authors:  D Short
Journal:  Am Heart J       Date:  1977-08       Impact factor: 4.749

9.  Metabolic studies in patients with nadolol: oral and intravenous administration.

Authors:  J Dreyfuss; L J Brannick; R A Vukovich; J M Shaw; D A Willard
Journal:  J Clin Pharmacol       Date:  1977 May-Jun       Impact factor: 3.126

10.  Treatment of angina pectoris. Pharmacologic approaches.

Authors:  W S Aronow
Journal:  Postgrad Med       Date:  1976-11       Impact factor: 3.840

View more
  2 in total

1.  Diacetyl nadolol: 3-month ocular hypotensive effect in glaucomatous eyes.

Authors:  E Duzman; N Rosen; M Lazar
Journal:  Br J Ophthalmol       Date:  1983-10       Impact factor: 4.638

Review 2.  Nadolol: a review of its pharmacological properties and therapeutic efficacy in hypertension and angina pectoris.

Authors:  R C Heel; R N Brogden; G E Pakes; T M Speight; G S Avery
Journal:  Drugs       Date:  1980-07       Impact factor: 9.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.